CytoMed Therapeutics GDTC
NASDAQ GDTC
$0.91 +0.04 (+4.42%)
As of: Oct 21, 2026 · 3:59 PM EDT

CytoMed Therapeutics (GDTC) Notes Payables (2021 - 2026)

Updated

CytoMed Therapeutics (GDTC) reported Notes Payables of $31,517 for Q4 2025, up 11.3% from $28,304 a year earlier.

Analysis

CytoMed Therapeutics (GDTC) Notes Payables (2021 - 2026) Analysis & Trends

At the end of FY2025, CytoMed Therapeutics posted Notes Payables of $31,765, up 15.3% from FY2024.

  • Notes Payables has a four-year compound annual growth rate of -42.3% (FY2021 to FY2025).
  • By year, Notes Payables came in at $27,558 in FY2024 (+7.2%), $25,715 in FY2023 (-26.1%), $34,779 in FY2022 (-87.9%) and $287,127 in FY2021.
  • The Q4 2025 figure ranks as the highest quarterly Notes Payables since Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,167.17 Bn 1,135.76 Bn 19.71 Bn
2 Johnson & Johnson 633.70 Bn 552.23 Bn 17.26 Bn
3 AbbVie 503.94 Bn 477.06 Bn 12.70 Bn
4 Merck 378.10 Bn 332.47 Bn 12.21 Bn
5 Novartis Ag 303.72 Bn 267.71 Bn 11.24 Bn
6 Astrazeneca 266.46 Bn 240.15 Bn 12.86 Bn
7 Amgen 241.07 Bn 196.47 Bn 7.24 Bn
8 Gilead Sciences 194.22 Bn 168.41 Bn 6.22 Bn
9 Pfizer 172.39 Bn 119.04 Bn 10.94 Bn
10 CytoMed Therapeutics 10.29 Mn 1.11 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 41,845.00
Dec 31, 2025 31,814.78
Jun 30, 2025 38,264.00
Dec 31, 2024 27,698.69
Jun 30, 2024 34,824.00
Dec 31, 2023 25,705.41
Jun 30, 2023 33,458.00
Dec 31, 2022 249,180.50
Dec 31, 2021 285,293.41
API Access

CytoMed Therapeutics Notes Payables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=notes-payables&ticker=GDTC&period=max&api_key=YOUR_API_KEY